Evidence map›Paper›PMID 42388795›Full record

ArticlebioRxiv : the preprint server for biology2026

Real-time, automated, standardized, and transparent analysis of microfluidic nanoparticle data with RPS

Michelle L Pleet, Sean Cook, Bryce Killingsworth, Tim Traynor, Dove-Anna Johnson, Emily H Stack, Verity Ford, Cláudio Pinheiro, Jessie E Arce, Jason Savage and 7 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Michelle L PleetViral Immunology Section, Neuroimmunology Branch, NINDS/NIH, Bethesda, MD, USA.ORCID 0000-0003-0102-711X
Sean CookTranslational Nanobiology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Bryce KillingsworthTranslational Nanobiology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Tim TraynorTranslational Nanobiology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Dove-Anna JohnsonTranslational Nanobiology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Emily H StackViral Immunology Section, Neuroimmunology Branch, NINDS/NIH, Bethesda, MD, USA.ORCID 0009-0008-0115-7321
Verity FordCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-1364-8522
Cláudio PinheiroLaboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium.ORCID 0000-0003-1834-199X
Jessie E ArceDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Jason SavageTranslational Nanobiology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Matthew RothDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Aleksandar MilosavljevicDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0001-5482-2825
Ionita GhiranDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6655-3298
An HendrixLaboratory of Experimental Cancer Research, Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
Steven JacobsonViral Immunology Section, Neuroimmunology Branch, NINDS/NIH, Bethesda, MD, USA.
Joshua A WelshTranslational Nanobiology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-1097-9756
Jennifer C JonesTranslational Nanobiology Section, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-9488-7719

Funding

Development and use of nanoFACS for analysis and sorting of nanoparticlesZIABC011502 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI JONES, JENNIFER · 2013 to 2025
$8.6M
Novel Combinations of Radiation and ImmunotherapyZIABC011503 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI JONES, JENNIFER · 2013 to 2025
$5.3M
Scientific Outreach ComponentU54DA049098 · NIDA · BAYLOR COLLEGE OF MEDICINE · PI GALAS, DAVID J., GERSTEIN, MARK BENDER · 2019 to 2022
$5.0M
Integrative, multi-parametric characterization of the EV surface protein and nucleic acid landscape by nano-flow and sorting cytometryUH3TR002881 · NCATS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI GHIRAN, IONITA CALIN, JONES, JENNIFER · 2021 to 2022
$1.9M
Intramural NIH HHS ZIA BC011502Intramural NIH HHS ZIA BC011503NCATS NIH HHS UH3 TR002881NIDA NIH HHS U54 DA049098
6 · The paper itself

Abstract

Extracellular vesicles (EVs) are lipid spheres released from cells. Research utilizing EVs has met several hurdles owing to the small size of the majority of EVs and other nanoparticles (<150 nm) and the lack of detection technologies capable of providing high-throughput single particle measurements at this scale. The use of high-throughput single particle measurements is critical for the assessment of EV heterogeneity and abundance which are features often used to assess the development of isolation protocols or particle characterization. The Coulter principle, known in the field as resistive pulse sensing (RPS), has been used for several decades to size and count cells. More recently, this technology has evolved to accommodate nanoparticle analysis. In the last decade a platform utilizing microfluidic resistive pulse sensing (MRPS) has been demonstrated for nanoparticles, offering ergonomic characterization of nanoparticles along with utilizing open format data. To date, assessment of MRPS accuracy and reporting standards have not been assessed. With the aim of increasing data accuracy, ergonomics, and reporting transparency, we developed a microfluidic resistive pulse sensing post-acquisition analysis software (RPS

Identifiers

PMID42388795
PMCPMC13317600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.